Patents matching “formulation”

US 10052386

Progesterone formulations

Compass Therapeutics LLC · Granted Aug 21, 2018 · Expires Aug 16, 2038

US 10028949

Parenteral formulations of lipophilic pharmaceutical agents and methods for preparing and using the same

Platform Brightworks Two, Ltd. · Granted Jul 24, 2018 · Expires Jul 19, 2038

US 10028911

Sustained release formulation of methotrexate as a disease-modifying antirheumatic drug (DMARD) and an anti-cancer agent

Pacira Pharmaceuticals, Inc. · Granted Jul 24, 2018 · Expires Jul 19, 2038

US 10016452

Fibromodulin formulation for reducing corneal scarring

The Regents of the University of California · Granted Jul 10, 2018 · Expires Jul 5, 2038

US 10010534

Intravenous formulation and LC/MS/MS analysis method for GMC1

The Board of Regents of the University of Texas System · Granted Jul 3, 2018 · Expires Jun 28, 2038

US 10010612

Sustained delivery formulations of risperidone compounds

Indivior UK Limited · Granted Jul 3, 2018 · Expires Jun 28, 2038

US 10010599

Norovirus vaccine formulations

Takeda Vaccines, Inc. · Granted Jul 3, 2018 · Expires Jun 28, 2038

US 2018169113

HIGH CONCENTRATION FORMULATION

CASSIOPEA S P A [IT] · Granted Jun 21, 2018 · Expires Jun 16, 2038

US 9993529

Stable formulations of a hyaluronan-degrading enzyme

HALOZYME, INC. · Granted Jun 12, 2018 · Expires Jun 7, 2038

US 9980983

Peroxide formulations and methods and applicators for using the same

Aclaris Therapeutics, Inc. · Granted May 29, 2018 · Expires May 24, 2038

US 9980904

Dry powder formulation

Teva Branded Pharmaceutical Products R&D, Inc. · Granted May 29, 2018 · Expires May 24, 2038

US 9974744

Sustained release formulation of a non-steroidal anti-inflammatory drug

Pacira Pharmaceuticals, Inc. · Granted May 22, 2018 · Expires May 17, 2038

US 9974793

Emulsion formulations of aprepitant

Heron Therapeutics, Inc. · Granted May 22, 2018 · Expires May 17, 2038

US 9974794

Emulsion formulations of aprepitant

Heron Therapeutics, Inc. · Granted May 22, 2018 · Expires May 17, 2038

US 9974742

Emulsion formulations of an NK-1 receptor antagonist and uses thereof

Heron Therapeutics, Inc. · Granted May 22, 2018 · Expires May 17, 2038

US 9968598

Process of making stable abuse-deterrent oral formulations

Collegium Pharmaceutical, Inc. · Granted May 15, 2018 · Expires May 10, 2038

US 9962390

Mosapride sustained-release formulation providing pharmacological and clinical effects with once-daily administration

KOREA UNITED PHARM. INC. · Granted May 8, 2018 · Expires May 3, 2038

US 9956188

Eutectic formulations of cyclobenzaprine hydrochloride and amitriptyline hydrochloride

TONIX PHARMA LIMITED · Granted May 1, 2018 · Expires Apr 26, 2038

US 9949932

Formulation of syk inhibitors

GILEAD CONNECTICUT, INC. · Granted Apr 24, 2018 · Expires Apr 19, 2038

US 9943601

Etanercept formulations stabilized with combinations of sugars and polyols

Coherus BioSciences, Inc. · Granted Apr 17, 2018 · Expires Apr 12, 2038

US 9931419

Methods and compositions for liposomal formulation of antigens and uses thereof

The Regents of the University of California · Granted Apr 3, 2018 · Expires Mar 29, 2038

US 9918939

Formulation of Syk inhibitors

GILEAD CONNECTICUT, INC. · Granted Mar 20, 2018 · Expires Mar 15, 2038

US 9919063

Multi-encapsulated formulations made with oxidized cellulose

Covidien LP · Granted Mar 20, 2018 · Expires Mar 15, 2038

US 9919051

Liquid formulation comprising GM-CSF neutralizing compound

TAKEDA GMBH · Granted Mar 20, 2018 · Expires Mar 15, 2038